UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
______________
|
Pursuant
to Section 13 or 15(d) of
|
|
The
Securities Exchange Act of 1934
|
|
Date
of Report: (Date of earliest event
reported): July 13,
2009
|
LIFE
SCIENCES RESEARCH, INC.
(EXACT
NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
MARYLAND
(State or
other jurisdiction of incorporation)
0-33505
|
|
52-2340150
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification Number)
|
|
|
|
|
|
|
PO
Box 2360, Mettlers Road, East Millstone, NJ
|
|
08875
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(732)
649-9961
|
(Former
name or former address, if changed since last
report)
|
Item
8.01
.
Other
Events
Life Sciences Research, Inc. (the
“Company”) reports the filing on July 13, 2009 of a First Amended Complaint in
the previously disclosed purported class action lawsuit,
Berger v. Life Sciences
Research, et al
., against the Company in connection with the Company’s
entry into a definitive merger agreement on July 8, 2009 with Lion Holdings,
Inc. and its subsidiary Lion Merger Corp. (collectively, “Lion”), entities
controlled by Andrew Baker, pursuant to which Lion would acquire all of the
outstanding shares of the Company for $8.50 per share (the “Baker
Merger”).
The First Amended Complaint, like the
original lawsuit, was filed in Superior Court of New Jersey, Chancery Division,
Somerset County (Civil Action No. SOM-C-12006-09), and names as defendants Mr.
Baker, all other members of the Company’s Board of Directors and the
Company. The First Amended Complaint alleges, among other things,
that the directors breached their fiduciary duties with respect to the Baker
Merger; that Baker controls LSR and its directors; that the merger price
constitutes inadequate consideration; and that certain terms of the merger
agreement unfairly benefit Mr. Baker at the expense of the other stockholders,
including the absence of appraisal rights, accelerated vesting of restricted
stock, restrictions on the solicitation of negotiations with respect to third
party proposals, and termination fees. The First Amended Complaint
further alleges that the directors were motivated to accept Baker’s offer
because of concerns that a public dispute with Baker would draw unwanted
attention from animal rights activists. The First Amended Complaint
seeks unspecified damages and other relief.
The Company also reports the filing on
July 17, 2009 of a second purported class action lawsuit,
Ramaiah v. Baker, et
al
. The complaint was filed in Superior Court of New Jersey,
Chancery Division, Somerset County and names as defendants Mr. Baker, all other
members of the Company’s Board, the Company and Lion. This complaint
also alleges, among other things, that the Board breached its fiduciary duties
in connection with the Baker Merger by agreeing to sell the Company for an
unfair price pursuant to an unfair process and that the merger agreement
contains preclusive deal protection provisions by virtue of its “no shop” and
“standstill” clauses and termination fees. This complaint seeks
unspecified damages and other relief.
The Company will respond appropriately
to both of these lawsuits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act 1934, Life Sciences Research,
Inc. has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: July
24, 2009
|
LIFE
SCIENCES RESEARCH, INC.
|
|
|
|
|
|
By: /s/
Mark L. Bibi
|
|
Name: Mark
L. Bibi
|
|
Title: Secretary
and General Counsel
|